NF-kB activity was evaluated in PBMCs of 36 ALL patients (26 pre-B ALL and 10 T-ALL) and 12 AML patients at three time points: T = 0, T = 6 and T = 24 h after the first bortezomib administration. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.